Search by Title Article Topic - Any -AdvocacyAnnual Scientific MeetingAwardsBoard Certification ReviewCertificationClinical DocumentClinical TrialsCoronavirusEarly CareerFellowshipFuture LeadersHeart Failure Awareness 365Heart Failure GuidelinesHF Research FoundationHFSA CommitteesHFSA Comprehensive Heart Failure ReviewHFSA Learning CenterIn The NewsIndustryJournal of Cardiac FailureLeadershipMembershipMentorshipNursingPartnersPatient ResourcePatient StoryPodcastsPresident's UpdatesPress ReleaseProfessional DevelopmentProvider EducationResearchSocial MediaStatementSubmissionsWomen in Heart Failure Article Type - Any -HFSA NewsIndustry NewsPatient NewsPractice News Nov 15 2025 | Revisiting the Fundamentals: Hemodynamics at the Heart of Heart Failure Care HFSA News Podcasts Read More Nov 12 2025 | Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Industry News Industry Read More Nov 11 2025 | Breakthrough Insights into Hemodynamics Featured in Journal of Cardiac Failure November Issue HFSA News Journal of Cardiac Failure Press Release Read More Nov 10 2025 | Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial Industry News Industry Read More Nov 7 2025 | KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease Industry News Industry Read More Pagination First page « First Previous page ‹ Previous … Page 2 Page 3 Page 4 Page 5 Current page 6 Page 7 Page 8 Page 9 Page 10 … Next page Next › Last page Last »
Nov 15 2025 | Revisiting the Fundamentals: Hemodynamics at the Heart of Heart Failure Care HFSA News Podcasts Read More
Nov 12 2025 | Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations Industry News Industry Read More
Nov 11 2025 | Breakthrough Insights into Hemodynamics Featured in Journal of Cardiac Failure November Issue HFSA News Journal of Cardiac Failure Press Release Read More
Nov 10 2025 | Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial Industry News Industry Read More
Nov 7 2025 | KERENDIA® (finerenone) Meets Primary Endpoint in Phase III Clinical Trial for Adults with Type 1 Diabetes and Chronic Kidney Disease Industry News Industry Read More
